• ​Total revenue in the first quarter of 2026 amounted to 154.7 million euros, in line with the same period of the previous year.
• Operating revenue in the first quarter of 2026 was 152.5 million euros, a 1.5% decrease on the first quarter of 2025, mainly due to the performance of the heparin franchise. However, sales of the contract development and manufacturing business ("CDMO") increased 5% to 37.4 million euros in the first quarter of 2026.
• Positive evolution of Okedi® (Risperidone ISM®), which obtained sales of 17.2 million euros in the first quarter of 2026. Okedi® sales increased by 37% in the first quarter of 2026 compared to the first quarter of 2025 and 10% compared to the fourth quarter of 2025, which was the strongest quarter of the year.
• Sales of the heparin franchise (which includes low-molecular-weight heparins (LMWH) and other heparins) decreased by 12% to 61.4 million euros in the first quarter of 2026. This decrease was mainly attributable to the weaker performance of bemiparin, particularly in international sales, as a result of high inventory levels held by partners.
• Neparvis® continued to deliver solid performance, with sales growing by 4% in the first quarter of 2026 compared to the same period in 2025, reaching 14.2 million euros.
• On 1 April 2026, ROVI announced that the Asset Purchase Agreement signed between its subsidiary ROIS Phoenix Inc. and Bristol Myers Squibb for the acquisition of a pharmaceutical manufacturing plant located in Phoenix, Arizona (United States of America) together with a series of related assets and liabilities had been executed. The consummation of the aforementioned Asset Purchase Agreement took place upon the satisfaction of the customary closing conditions for transactions of this nature and in the absence of any material adverse change since its execution.
• Gross profit increased by 5% in the first quarter of 2026 compared to the first quarter of 2025, reaching 95.0 million euros. Gross margin showed an increase of 3.8 percentage points year-on-year to 62.3% in 2026. This increase was impacted by the recognition of revenue associated with the R&D aid awarded by the CDTI for the LAISOLID project, which is recorded under the "Other income" line. However, excluding the impact of "Other income", gross margin would have increased by 2.5 percentage points to 60.8% mainly due to: (i) the increased contribution of Okedi® sales, which added high margins, (ii) the decrease in LMWH raw material prices, which had a positive impact on gross margin, and (iii) the increase in the CDMO business which contributed higher margins to Group sales.
• Net profit amounted to 9.4 million euros in the first quarter of 2026. OUTLOOK ROVI has updated its operating revenue guidance for 2026 in the light of the current performance of certain business variables and the latest information available.

OUTLOOK

ROVI has updated its operating revenue guidance for 2026 in the light of the current performance of certain business variables and the latest information available.

In this context, ROVI expects its operating revenue to continue to increase compared to 2025, although by a low- to mid-single-digit percentage. This is a more moderate growth scenario for 2026 than previously announced and is subject to various factors, whose development remains difficult to predict accurately. Among the main factors that have caused this update to the guidance and been taken into account when preparing it, the following may be highlighted:

• Lower revenue forecast for 2026 under the prefilled syringe manufacturing agreement entered into with a global pharmaceutical company, which was disclosed as inside information on 25 April 2024. The adjustment to the guidance is due, among other factors, to a delay in the initially expected commencement of routine manufacturing operations, which is awaiting the relevant regulatory authorization, as well as increased uncertainty regarding anticipated demand, without prejudice to the minimum contractual obligations assumed by the two parties; and
• Growing competitive pressure on pricing in the heparin franchise in the current context of increased regulatory and geopolitical uncertainty and greater volatility in supply and cost dynamics. Additionally, the heparin franchise performed better than expected in 2025, mainly due to an increase in orders from international partners. Therefore, we expect lower orders from these partners in 2026 since they hold a high level of stocks.

At any event, the Company is taking a prudent approach to its guidance for 2026, reflecting the competitive environment and the current visibility of its main lines of business, which it will continue to monitor closely.